These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4567423)

  • 41. [Physiopathology of protein and lipid metabolism in the nephrotic syndrome. Recent experimental and clinical data].
    Costică II; Dumitriu M
    Fiziol Norm Patol; 1972; 18(2):145-54. PubMed ID: 5032189
    [No Abstract]   [Full Text] [Related]  

  • 42. [Diagnosis and therapy of symptomatic and essential hyperlipidemia].
    Dabels J
    Z Gesamte Inn Med; 1971 Apr; 26(8):261-5. PubMed ID: 5565821
    [No Abstract]   [Full Text] [Related]  

  • 43. [Preliminary studies on the effects of CoA administration on plasmatic lipids in man].
    Arrigo F; Vitale D; Consolo F
    Boll Soc Ital Biol Sper; 1973 Mar; 49(5):305-10. PubMed ID: 4786567
    [No Abstract]   [Full Text] [Related]  

  • 44. [Disorders of lipid metabolism in patients with nephrotic syndrome].
    Zdrojewski Z
    Pol Tyg Lek; 1992 Aug 7-17; 47(31-33):696-9. PubMed ID: 1492041
    [No Abstract]   [Full Text] [Related]  

  • 45. THE EFFECT OF SF 20-10-5 CONCENTRATION CHANGES INDUCED BY ETHYL CHLOROPHENOXYISOBUTYRATE ON HIGH-DENSITY LIPOPROTEIN LIPID COMPOSITION.
    STRISOWER EH; NICHOLS AV; LINDGREN FT; SMITH L
    J Lab Clin Med; 1965 May; 65():748-55. PubMed ID: 14281371
    [No Abstract]   [Full Text] [Related]  

  • 46. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies on the pharmacological control of hyperlipemia in experimental nephrotic syndrome.
    Edwards KD; Usardi MM; Galli C; Paoletti R
    Biochem Pharmacol; 1970 Oct; 19(10):2719-25. PubMed ID: 5478582
    [No Abstract]   [Full Text] [Related]  

  • 48. [Studies on the effect of d-thyroxine in patients with increased serum lipid level].
    Steger H
    Wien Klin Wochenschr; 1968 Nov; 80(47):887-98. PubMed ID: 5717659
    [No Abstract]   [Full Text] [Related]  

  • 49. [Lipid transport in blood from the protein chemistry viewpoint].
    Titov VN
    Vopr Pitan; 1995; (2):9-13. PubMed ID: 7483472
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical experimentation of clofibride. Apropos of 40 cases].
    Warembourg H; Jaillard J
    Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1292-6. PubMed ID: 4802928
    [No Abstract]   [Full Text] [Related]  

  • 51. [Lipid metabolism in kidney diseases].
    Yoshitoshi Y; Naito C
    Naika; 1968 Oct; 22(4):824-30. PubMed ID: 4884620
    [No Abstract]   [Full Text] [Related]  

  • 52. [Lipids and hyperlipoproteinemia].
    Magnenat G
    Ther Umsch; 1970 Sep; 27(9):566-73. PubMed ID: 5508271
    [No Abstract]   [Full Text] [Related]  

  • 53. Maternal lipid metabolism.
    Biezenski JJ
    Obstet Gynecol Annu; 1974; 3(0):203-33. PubMed ID: 4609037
    [No Abstract]   [Full Text] [Related]  

  • 54. Disorders of blood-lipids in renal disease.
    Cramp DG; Moorhead JF; Wills MR
    Lancet; 1975 Mar; 1(7908):672-3. PubMed ID: 47091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The possible means for the pharmacological correction of lipid metabolic disorders in atherosclerosis].
    Piskun RP; Pentiuk AA; Serkova VK; Polesia TL; Savitskaia EA
    Eksp Klin Farmakol; 1997; 60(2):78-85. PubMed ID: 9206580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical and therapeutic evaluation of a new antilipemic substance].
    de Aguiar Magano L
    Arch Sci Med (Torino); 1980; 137(1):131-9. PubMed ID: 7458646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Inborn errors of lipid metabolism. Effect of clofibrate on the level of blood lipids of patients with familial hyperlipoproteinemia (type 2, 3 and 4)].
    Sobra J; Heyrovský A; Sulc M; Horáková D
    Cas Lek Cesk; 1969 Aug; 108(36):1065-9. PubMed ID: 5807234
    [No Abstract]   [Full Text] [Related]  

  • 58. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical-experimental studies on lipid metabolism using Regelan].
    Hammerl H
    Wien Klin Wochenschr; 1967 Sep; 79(39):720-2. PubMed ID: 4875575
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.